Estimation of economic costs associated with transfusion dependence in adults with MDS

Current Medical Research and Opinion

Volumn 25, Issue 8, 2009, Pages 1941-1951

  Frytak, Jennifer R ^a   Henk, Henry J ^a   De Castro, Carlos M ^b   Halpern, Rachel ^a   Nelson, Michael ^a  

^a MN002 0258 ^*  (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Blood transfusion; Health care costs; Myelodysplastic syndromes (MDS)

Indexed keywords

AGED; ARTICLE; BLOOD TRANSFUSION; COMORBIDITY; CONTROLLED STUDY; DATA BASE; EMERGENCY WARD; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH STATUS; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MYELODYSPLASTIC SYNDROME; OUTPATIENT; PHYSICIAN; UNITED STATES;

AGED; BLOOD TRANSFUSION, AUTOLOGOUS; COHORT STUDIES; COST OF ILLNESS; COSTS AND COST ANALYSIS; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; UNITED STATES;

EID: 67650809004     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903076699     Document Type: Article

References (20)

1. Kouides PA, Bennett JM. Understanding myelodysplastic syndromes: a patient handbook. Available at: http://www.mdsfoundation. org/articles/articles- handbook-understanding-mds.htm [Last accessed 7 January 2009]
2. Bennett JM. The myelodysplastic syndromes: a review for patients, families, friends, and healthcare professionals. Available at: http://www.mds-foundation.org/patientinfo.htm [Last accessed 7 January 2009]
3. Gupta P, LeRoy SC, Luikart SD, et al. Long-term blood transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res 1999;23:953-9
4. Maschek H, Gutzmer R, Choritz H, et al. Life expectancy in primary myelodysplastic syndromes: a prognostic score based upon histopathology from bone marrow biopsies of 569 patients. Eur J Haematol 1994;53:280-7
5. Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res 2003;27:95-120
6. Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: A randomized, controlled trial. Blood 2004;104:321-7
7. Remacha AF, Arrizabalaga B, Villegas A, et al. for the Spanish Erythropathology Group. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. Haematologica 1999;84:1058-64
8. Musto P, Falcone A, Sanpaolo G, et al. Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes. Haematologica 2002;87:884-6
9. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-57
10. Garcia-Manero G, Yang AS, Jagasia M. Evaluating new treatment options for MDS. Clin Adv Hematol Oncol 2007;5:1-9
11. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-603
12. Thomas ML. Quality of life and psychosocial adjustment in patients with myelodysplastic syndromes. Leuk Res 1998; 22(Suppl.):S41-7
13. Amin M, Fergusson D, Wilson K, et al. The societal unit cost of allogenic red blood cells and red blood cell transfusion in Canada. Transfusion 2004;44:1479-86
14. Amin, M, Fergusson D, Aziz A, et al. The cost of allogeneic red blood cells - a systematic review. Transfus Med 2003;13:275-85
15. Cremieux, PY, Barrett B, Anderson K, et al. Cost of outpatient blood transfusion in cancer patients. J Clin Oncol 2000; 18:2755-61
16. Agency for Healthcare Research and Quality. Comorbidity Software, Version 3.0. Available at: http://www.hcup-us.ahrq. gov/toolssoftware/comorbidity/ comorbidity.jsp [Last accessed 7 January 2009]
17. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461-94
18. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 1998; 17:283-95
19. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York: Chapman & Hall, 1993
20. Manning WG, Fryback DG, Weinstein MC. Reflecting uncertainty in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, Weinstein MC (eds) Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996: 247-75